Tracks new irregular heartbeat in adults after a heart attack
Uses a continuous electronic monitor to track new atrial fibrillation after heart attack.
Plain-language title generated from the registry record
Registry title: BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Key facts
- Where
- Kaifeng, Luoyang, Shanghai, and Zhengzhou, ChinaSee the 5 sites
Where in China
- Kaifeng Central HospitalKaifeng, ChinaTaking people
- Luoyang Central HospitalLuoyang, ChinaTaking people
- Department of Cardiology, Shanghai Tenth People's HospitalShanghai, ChinaTaking people
- Shanghai Seventh People's HospitalShanghai, ChinaTaking people
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 10th People's Hospital
- Trial code
- NCT04528511
- Record updated
- 19 March 2026
- Original description
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.Read full original descriptionShow less
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.
Inclusion: Adult patients (>18 years old); Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; Patients must have received in-hospital CEM for at least 5 days; Patients must give informed consent.
Exclusion: Patients undergoing emergent coronary artery bypass surgery; Patients with a medical history of pre-existing AF; Patients with a medical history of rheumatic valvular disease; Patients with a medical history of sick sinus syndrome; Patients who suffer malignant tumors with an expected lifetime less than 1 year ; Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; Patients who have died during the index hospitalization.